Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hypertension, Portal | 53 | 2024 | 229 | 9.190 |
Why?
|
Liver Cirrhosis | 69 | 2024 | 1959 | 4.450 |
Why?
|
Portal Pressure | 28 | 2024 | 62 | 2.840 |
Why?
|
Genome, Protozoan | 4 | 2024 | 153 | 2.150 |
Why?
|
Esophageal and Gastric Varices | 15 | 2024 | 215 | 1.730 |
Why?
|
Trypanosoma cruzi | 5 | 2023 | 200 | 1.680 |
Why?
|
Hepatitis C, Chronic | 19 | 2022 | 1032 | 1.620 |
Why?
|
Elasticity Imaging Techniques | 17 | 2021 | 398 | 1.510 |
Why?
|
Ascites | 12 | 2023 | 336 | 1.370 |
Why?
|
Hepatitis C | 18 | 2022 | 1597 | 1.260 |
Why?
|
Malaria, Falciparum | 4 | 2024 | 1075 | 1.190 |
Why?
|
Liver | 28 | 2024 | 7562 | 0.980 |
Why?
|
Malaria, Vivax | 2 | 2024 | 168 | 0.970 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 6 | 2024 | 852 | 0.930 |
Why?
|
Leishmania infantum | 2 | 2021 | 17 | 0.900 |
Why?
|
DNA, Protozoan | 3 | 2021 | 226 | 0.880 |
Why?
|
Plasmodium vivax | 2 | 2024 | 202 | 0.850 |
Why?
|
Leishmaniasis, Visceral | 2 | 2021 | 99 | 0.830 |
Why?
|
DNA Barcoding, Taxonomic | 2 | 2020 | 135 | 0.780 |
Why?
|
Austria | 18 | 2023 | 206 | 0.750 |
Why?
|
Plasmodium falciparum | 5 | 2024 | 1738 | 0.730 |
Why?
|
Peritonitis | 4 | 2016 | 369 | 0.710 |
Why?
|
Genes, Protozoan | 1 | 2021 | 170 | 0.700 |
Why?
|
Liver Diseases | 9 | 2023 | 1303 | 0.700 |
Why?
|
Gastrointestinal Hemorrhage | 15 | 2024 | 1127 | 0.680 |
Why?
|
Phosphodiesterase 5 Inhibitors | 1 | 2020 | 103 | 0.660 |
Why?
|
Benzoates | 2 | 2020 | 213 | 0.640 |
Why?
|
Liver Cirrhosis, Experimental | 3 | 2024 | 30 | 0.600 |
Why?
|
Ligation | 8 | 2022 | 444 | 0.600 |
Why?
|
Meiosis | 1 | 2019 | 326 | 0.570 |
Why?
|
Adrenergic beta-Antagonists | 7 | 2021 | 1237 | 0.550 |
Why?
|
Metagenomics | 1 | 2020 | 473 | 0.550 |
Why?
|
Metagenome | 1 | 2020 | 464 | 0.540 |
Why?
|
Antiviral Agents | 15 | 2022 | 3050 | 0.530 |
Why?
|
Parasitic Diseases | 1 | 2016 | 76 | 0.530 |
Why?
|
Interferons | 5 | 2019 | 714 | 0.510 |
Why?
|
HIV Infections | 17 | 2022 | 17533 | 0.510 |
Why?
|
Varicose Veins | 3 | 2022 | 158 | 0.500 |
Why?
|
Chagas Disease | 3 | 2023 | 163 | 0.500 |
Why?
|
Ascitic Fluid | 4 | 2021 | 190 | 0.480 |
Why?
|
Anemia | 2 | 2022 | 1511 | 0.480 |
Why?
|
Isoxazoles | 1 | 2016 | 234 | 0.480 |
Why?
|
Malaria | 2 | 2022 | 1246 | 0.480 |
Why?
|
Host-Parasite Interactions | 1 | 2016 | 302 | 0.460 |
Why?
|
Jugular Veins | 3 | 2020 | 211 | 0.460 |
Why?
|
von Willebrand Factor | 4 | 2023 | 676 | 0.450 |
Why?
|
Evolution, Molecular | 2 | 2021 | 1889 | 0.420 |
Why?
|
Feces | 1 | 2019 | 1504 | 0.400 |
Why?
|
Portasystemic Shunt, Transjugular Intrahepatic | 3 | 2018 | 95 | 0.400 |
Why?
|
Pyrazoles | 2 | 2020 | 2033 | 0.370 |
Why?
|
Hepacivirus | 11 | 2022 | 1343 | 0.360 |
Why?
|
Thiazolidinediones | 1 | 2014 | 459 | 0.360 |
Why?
|
Molecular Epidemiology | 2 | 2024 | 471 | 0.350 |
Why?
|
Bacterial Infections | 3 | 2016 | 1387 | 0.350 |
Why?
|
Venous Pressure | 2 | 2020 | 55 | 0.340 |
Why?
|
P-Selectin | 2 | 2023 | 597 | 0.340 |
Why?
|
Lipase | 3 | 2018 | 320 | 0.330 |
Why?
|
Hepatic Veins | 2 | 2020 | 112 | 0.330 |
Why?
|
Pyrimidines | 2 | 2020 | 3047 | 0.330 |
Why?
|
Ribavirin | 5 | 2018 | 395 | 0.330 |
Why?
|
Rats, Sprague-Dawley | 8 | 2021 | 8102 | 0.320 |
Why?
|
Paracentesis | 4 | 2018 | 99 | 0.310 |
Why?
|
Neovascularization, Pathologic | 4 | 2019 | 2631 | 0.310 |
Why?
|
Rats | 11 | 2024 | 23707 | 0.300 |
Why?
|
Hemodynamics | 9 | 2022 | 4184 | 0.300 |
Why?
|
Chiroptera | 2 | 2019 | 62 | 0.300 |
Why?
|
Fibrosis | 2 | 2015 | 2070 | 0.290 |
Why?
|
End Stage Liver Disease | 3 | 2020 | 369 | 0.290 |
Why?
|
Middle Aged | 65 | 2024 | 223009 | 0.290 |
Why?
|
Fluorenes | 3 | 2018 | 160 | 0.290 |
Why?
|
Communicable Diseases, Emerging | 2 | 2019 | 150 | 0.280 |
Why?
|
Bile Ducts | 2 | 2020 | 288 | 0.280 |
Why?
|
Male | 75 | 2024 | 363698 | 0.280 |
Why?
|
Bile Acids and Salts | 3 | 2024 | 398 | 0.270 |
Why?
|
Drug Resistance | 2 | 2024 | 1591 | 0.270 |
Why?
|
Humans | 114 | 2024 | 765968 | 0.270 |
Why?
|
Genomics | 3 | 2024 | 5929 | 0.270 |
Why?
|
Genetic Variation | 5 | 2024 | 6610 | 0.260 |
Why?
|
Liver Failure | 2 | 2018 | 252 | 0.260 |
Why?
|
Disease Models, Animal | 6 | 2024 | 18293 | 0.260 |
Why?
|
Liver Neoplasms | 5 | 2023 | 4353 | 0.260 |
Why?
|
Platelet Activation | 3 | 2023 | 645 | 0.250 |
Why?
|
Vascular Resistance | 2 | 2020 | 941 | 0.250 |
Why?
|
Proline | 3 | 2017 | 453 | 0.240 |
Why?
|
Fatty Liver | 4 | 2019 | 807 | 0.230 |
Why?
|
Hepatorenal Syndrome | 2 | 2016 | 76 | 0.230 |
Why?
|
Splanchnic Circulation | 3 | 2014 | 122 | 0.230 |
Why?
|
HIV Seropositivity | 2 | 2022 | 961 | 0.220 |
Why?
|
Portal System | 2 | 2020 | 49 | 0.220 |
Why?
|
Female | 69 | 2024 | 396112 | 0.220 |
Why?
|
Retrospective Studies | 39 | 2023 | 81514 | 0.220 |
Why?
|
Passeriformes | 1 | 2023 | 3 | 0.220 |
Why?
|
Panstrongylus | 1 | 2023 | 1 | 0.220 |
Why?
|
Benzimidazoles | 3 | 2018 | 864 | 0.210 |
Why?
|
Triatoma | 1 | 2023 | 10 | 0.210 |
Why?
|
Triatominae | 2 | 2020 | 6 | 0.210 |
Why?
|
Ecuador | 2 | 2020 | 62 | 0.210 |
Why?
|
Liver Function Tests | 3 | 2023 | 525 | 0.210 |
Why?
|
Inflammation | 8 | 2024 | 10850 | 0.210 |
Why?
|
Hepatitis, Viral, Human | 2 | 2020 | 141 | 0.200 |
Why?
|
Bacterial Translocation | 2 | 2023 | 74 | 0.200 |
Why?
|
Corticosterone | 1 | 2023 | 301 | 0.200 |
Why?
|
Animals | 22 | 2024 | 168764 | 0.200 |
Why?
|
Imidazoles | 3 | 2016 | 1162 | 0.190 |
Why?
|
Severity of Illness Index | 16 | 2023 | 15880 | 0.190 |
Why?
|
Adult | 41 | 2024 | 223044 | 0.190 |
Why?
|
Blood Coagulation Factors | 2 | 2021 | 371 | 0.190 |
Why?
|
Hemiptera | 1 | 2020 | 7 | 0.180 |
Why?
|
Hyponatremia | 1 | 2024 | 276 | 0.180 |
Why?
|
Liver Circulation | 3 | 2021 | 163 | 0.180 |
Why?
|
Liver Cirrhosis, Biliary | 1 | 2021 | 107 | 0.180 |
Why?
|
Disease Vectors | 1 | 2020 | 61 | 0.180 |
Why?
|
Lipopolysaccharides | 3 | 2023 | 2216 | 0.180 |
Why?
|
Acute Kidney Injury | 4 | 2017 | 1946 | 0.180 |
Why?
|
Trypanosoma rangeli | 1 | 2020 | 1 | 0.180 |
Why?
|
Thrombocytosis | 1 | 2021 | 87 | 0.180 |
Why?
|
Uridine Monophosphate | 2 | 2018 | 67 | 0.180 |
Why?
|
Splenectomy | 1 | 2022 | 390 | 0.170 |
Why?
|
Plastics | 1 | 2020 | 117 | 0.170 |
Why?
|
Dielectric Spectroscopy | 1 | 2020 | 30 | 0.170 |
Why?
|
17-Hydroxysteroid Dehydrogenases | 1 | 2019 | 58 | 0.170 |
Why?
|
Fatty Liver, Alcoholic | 1 | 2020 | 36 | 0.170 |
Why?
|
Anemia, Iron-Deficiency | 2 | 2021 | 374 | 0.160 |
Why?
|
Spectroscopy, Fourier Transform Infrared | 1 | 2019 | 157 | 0.160 |
Why?
|
Brazil | 2 | 2021 | 1248 | 0.160 |
Why?
|
Kaplan-Meier Estimate | 7 | 2024 | 6499 | 0.160 |
Why?
|
Biopsy | 7 | 2021 | 6763 | 0.160 |
Why?
|
Extracellular Fluid | 1 | 2020 | 165 | 0.150 |
Why?
|
Leukocyte Count | 2 | 2020 | 1602 | 0.150 |
Why?
|
Phylogeny | 3 | 2021 | 2832 | 0.150 |
Why?
|
Platelet Count | 1 | 2021 | 782 | 0.150 |
Why?
|
Rodentia | 1 | 2019 | 261 | 0.150 |
Why?
|
Fibroblast Growth Factors | 1 | 2024 | 871 | 0.150 |
Why?
|
Complement C3 | 2 | 2022 | 424 | 0.140 |
Why?
|
Asia | 1 | 2019 | 628 | 0.140 |
Why?
|
Trypanosoma | 1 | 2017 | 14 | 0.140 |
Why?
|
Carcinoma, Hepatocellular | 2 | 2021 | 2329 | 0.140 |
Why?
|
RNA, Ribosomal, 18S | 1 | 2017 | 54 | 0.140 |
Why?
|
Antimalarials | 1 | 2024 | 913 | 0.140 |
Why?
|
Portal Vein | 2 | 2018 | 435 | 0.140 |
Why?
|
Virulence | 1 | 2020 | 1289 | 0.140 |
Why?
|
Collagen | 2 | 2022 | 2618 | 0.130 |
Why?
|
Interleukin-6 | 3 | 2022 | 3222 | 0.130 |
Why?
|
Water Pollutants, Chemical | 1 | 2020 | 358 | 0.130 |
Why?
|
Propanolamines | 2 | 2017 | 163 | 0.130 |
Why?
|
Gastroenterology | 1 | 2023 | 594 | 0.130 |
Why?
|
Venezuela | 3 | 2023 | 73 | 0.130 |
Why?
|
Sequence Deletion | 1 | 2021 | 1495 | 0.130 |
Why?
|
Cholestasis, Intrahepatic | 1 | 2016 | 75 | 0.130 |
Why?
|
Aged | 27 | 2024 | 171117 | 0.130 |
Why?
|
DNA, Ribosomal | 1 | 2017 | 300 | 0.130 |
Why?
|
Substance Abuse, Intravenous | 1 | 2020 | 531 | 0.130 |
Why?
|
Sarcopenia | 1 | 2020 | 378 | 0.120 |
Why?
|
Carbazoles | 2 | 2017 | 229 | 0.120 |
Why?
|
Biopsy, Needle | 1 | 2020 | 1628 | 0.120 |
Why?
|
Membrane Proteins | 3 | 2018 | 7851 | 0.120 |
Why?
|
Costs and Cost Analysis | 1 | 2020 | 1668 | 0.120 |
Why?
|
Actins | 1 | 2022 | 2056 | 0.120 |
Why?
|
Reproduction | 1 | 2019 | 641 | 0.120 |
Why?
|
Bilirubin | 1 | 2016 | 439 | 0.120 |
Why?
|
Recombination, Genetic | 1 | 2019 | 1525 | 0.120 |
Why?
|
Carbamates | 4 | 2017 | 191 | 0.120 |
Why?
|
Blood Coagulation Disorders | 1 | 2018 | 349 | 0.120 |
Why?
|
Renin | 1 | 2017 | 647 | 0.110 |
Why?
|
Genetics, Population | 1 | 2019 | 943 | 0.110 |
Why?
|
Valine | 4 | 2017 | 410 | 0.110 |
Why?
|
Exons | 1 | 2020 | 2391 | 0.110 |
Why?
|
Prognosis | 11 | 2023 | 29922 | 0.110 |
Why?
|
Communicable Diseases | 1 | 2022 | 874 | 0.110 |
Why?
|
Signal Transduction | 4 | 2024 | 23601 | 0.110 |
Why?
|
Transaminases | 1 | 2014 | 199 | 0.110 |
Why?
|
Capillaries | 1 | 2016 | 755 | 0.110 |
Why?
|
Gene Deletion | 1 | 2021 | 2666 | 0.110 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2017 | 664 | 0.100 |
Why?
|
Epidemics | 1 | 2019 | 514 | 0.100 |
Why?
|
Receptor, PAR-1 | 2 | 2023 | 109 | 0.100 |
Why?
|
Interleukins | 2 | 2015 | 791 | 0.100 |
Why?
|
Benzopyrans | 1 | 2013 | 62 | 0.100 |
Why?
|
Europe | 1 | 2019 | 3423 | 0.100 |
Why?
|
Mesenteric Artery, Superior | 1 | 2013 | 96 | 0.100 |
Why?
|
Receptors, Thrombin | 2 | 2023 | 130 | 0.100 |
Why?
|
Ethanolamines | 1 | 2013 | 152 | 0.100 |
Why?
|
Disease Progression | 6 | 2021 | 13632 | 0.100 |
Why?
|
Propranolol | 3 | 2022 | 492 | 0.100 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2018 | 888 | 0.090 |
Why?
|
Sequence Analysis, DNA | 2 | 2019 | 4772 | 0.090 |
Why?
|
PPAR gamma | 1 | 2014 | 483 | 0.090 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2019 | 16047 | 0.090 |
Why?
|
Multivariate Analysis | 4 | 2018 | 12056 | 0.090 |
Why?
|
Polymorphism, Genetic | 1 | 2020 | 4247 | 0.090 |
Why?
|
Pyrrolidines | 3 | 2016 | 337 | 0.080 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2022 | 2770 | 0.080 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2023 | 580 | 0.080 |
Why?
|
Drug Therapy, Combination | 5 | 2018 | 6309 | 0.080 |
Why?
|
Sodium | 1 | 2015 | 1591 | 0.080 |
Why?
|
Anticoagulants | 3 | 2023 | 4862 | 0.080 |
Why?
|
Heart Transplantation | 1 | 2023 | 3310 | 0.080 |
Why?
|
Platelet Aggregation | 2 | 2023 | 769 | 0.080 |
Why?
|
Hepatocytes | 1 | 2016 | 1247 | 0.080 |
Why?
|
Proton Pump Inhibitors | 1 | 2014 | 553 | 0.080 |
Why?
|
Predictive Value of Tests | 6 | 2021 | 15398 | 0.080 |
Why?
|
Epinephrine | 2 | 2023 | 783 | 0.080 |
Why?
|
Fatigue | 1 | 2016 | 1549 | 0.080 |
Why?
|
Stents | 2 | 2018 | 3213 | 0.080 |
Why?
|
Treatment Outcome | 14 | 2024 | 65188 | 0.080 |
Why?
|
Benzenesulfonates | 1 | 2009 | 170 | 0.080 |
Why?
|
Nitric Oxide | 2 | 2019 | 2143 | 0.080 |
Why?
|
Survival Analysis | 5 | 2019 | 10070 | 0.080 |
Why?
|
Statistics, Nonparametric | 1 | 2014 | 2844 | 0.080 |
Why?
|
Venous Thrombosis | 1 | 2018 | 1327 | 0.080 |
Why?
|
Drug Monitoring | 1 | 2014 | 962 | 0.080 |
Why?
|
Risk Factors | 11 | 2021 | 74840 | 0.070 |
Why?
|
Prospective Studies | 6 | 2023 | 54802 | 0.070 |
Why?
|
Homosexuality, Male | 3 | 2022 | 1342 | 0.070 |
Why?
|
Cholesterol | 1 | 2016 | 2898 | 0.070 |
Why?
|
Blood Platelets | 3 | 2023 | 2464 | 0.070 |
Why?
|
Albumins | 2 | 2021 | 577 | 0.070 |
Why?
|
Thrombosis | 1 | 2021 | 2949 | 0.070 |
Why?
|
Prevalence | 6 | 2023 | 15842 | 0.070 |
Why?
|
Creatinine | 3 | 2017 | 1915 | 0.070 |
Why?
|
Neutrophils | 1 | 2019 | 3776 | 0.060 |
Why?
|
Liver Transplantation | 4 | 2020 | 2412 | 0.060 |
Why?
|
Genotype | 5 | 2019 | 13024 | 0.060 |
Why?
|
Reproducibility of Results | 4 | 2020 | 20124 | 0.060 |
Why?
|
Risk Assessment | 3 | 2021 | 24282 | 0.060 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2024 | 10729 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2023 | 5891 | 0.060 |
Why?
|
Guyana | 1 | 2024 | 17 | 0.060 |
Why?
|
Mali | 1 | 2024 | 51 | 0.060 |
Why?
|
Logistic Models | 2 | 2019 | 13266 | 0.060 |
Why?
|
Arginine Vasopressin | 1 | 2024 | 125 | 0.050 |
Why?
|
Directly Observed Therapy | 1 | 2024 | 139 | 0.050 |
Why?
|
Receptors, Vasopressin | 1 | 2024 | 106 | 0.050 |
Why?
|
Young Adult | 4 | 2024 | 59889 | 0.050 |
Why?
|
Consensus | 2 | 2023 | 3202 | 0.050 |
Why?
|
Endemic Diseases | 1 | 2024 | 189 | 0.050 |
Why?
|
Cross-Sectional Studies | 6 | 2020 | 26318 | 0.050 |
Why?
|
Liver Cirrhosis, Alcoholic | 1 | 2022 | 64 | 0.050 |
Why?
|
Physicians | 1 | 2020 | 4588 | 0.050 |
Why?
|
Injections, Subcutaneous | 1 | 2024 | 682 | 0.050 |
Why?
|
Tissue Inhibitor of Metalloproteinases | 1 | 2022 | 97 | 0.050 |
Why?
|
Phenotype | 2 | 2019 | 16721 | 0.050 |
Why?
|
Life Cycle Stages | 1 | 2023 | 161 | 0.050 |
Why?
|
Proportional Hazards Models | 4 | 2018 | 12509 | 0.050 |
Why?
|
Vasopressins | 1 | 2024 | 359 | 0.050 |
Why?
|
Artemisinins | 1 | 2024 | 217 | 0.050 |
Why?
|
Cell Movement | 1 | 2014 | 5194 | 0.050 |
Why?
|
Child, Preschool | 1 | 2024 | 42500 | 0.050 |
Why?
|
ROC Curve | 2 | 2020 | 3620 | 0.050 |
Why?
|
Ileum | 1 | 2024 | 558 | 0.050 |
Why?
|
Hypoglycemic Agents | 1 | 2014 | 3110 | 0.050 |
Why?
|
alpha-Fetoproteins | 1 | 2021 | 226 | 0.050 |
Why?
|
Survival Rate | 3 | 2023 | 12795 | 0.050 |
Why?
|
Central Nervous System Depressants | 1 | 2021 | 163 | 0.040 |
Why?
|
Interferon-alpha | 2 | 2015 | 910 | 0.040 |
Why?
|
Angiopoietin-2 | 1 | 2022 | 187 | 0.040 |
Why?
|
Mass Screening | 2 | 2017 | 5446 | 0.040 |
Why?
|
Adenosine Diphosphate | 1 | 2022 | 419 | 0.040 |
Why?
|
Chronic Disease | 3 | 2021 | 9347 | 0.040 |
Why?
|
Hotlines | 1 | 2020 | 55 | 0.040 |
Why?
|
Polystyrenes | 1 | 2020 | 102 | 0.040 |
Why?
|
Antithrombins | 1 | 2023 | 295 | 0.040 |
Why?
|
Vitamin D | 1 | 2014 | 3272 | 0.040 |
Why?
|
Aquatic Organisms | 1 | 2020 | 42 | 0.040 |
Why?
|
Hepatic Stellate Cells | 1 | 2021 | 117 | 0.040 |
Why?
|
Cohort Studies | 6 | 2021 | 41649 | 0.040 |
Why?
|
Insulin Resistance | 1 | 2014 | 3985 | 0.040 |
Why?
|
Atlantic Ocean | 1 | 2019 | 24 | 0.040 |
Why?
|
Blood Coagulation Tests | 1 | 2021 | 263 | 0.040 |
Why?
|
Dialysis Solutions | 1 | 2020 | 33 | 0.040 |
Why?
|
Fibrinolysis | 1 | 2021 | 331 | 0.040 |
Why?
|
Loss of Heterozygosity | 1 | 2022 | 663 | 0.040 |
Why?
|
Myofibroblasts | 1 | 2021 | 229 | 0.040 |
Why?
|
Comorbidity | 3 | 2023 | 10563 | 0.040 |
Why?
|
Insect Vectors | 1 | 2020 | 136 | 0.040 |
Why?
|
Polyethylene Glycols | 2 | 2015 | 1188 | 0.040 |
Why?
|
Child | 2 | 2024 | 80564 | 0.040 |
Why?
|
Americas | 1 | 2019 | 109 | 0.040 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2021 | 428 | 0.040 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2020 | 110 | 0.040 |
Why?
|
Heart Failure | 1 | 2023 | 11840 | 0.040 |
Why?
|
MicroRNAs | 1 | 2015 | 3785 | 0.040 |
Why?
|
Peritoneal Dialysis | 1 | 2020 | 161 | 0.040 |
Why?
|
HIV | 2 | 2017 | 1585 | 0.040 |
Why?
|
C-Reactive Protein | 2 | 2020 | 3850 | 0.040 |
Why?
|
Genetic Fitness | 1 | 2019 | 119 | 0.040 |
Why?
|
Cholestasis | 1 | 2021 | 386 | 0.040 |
Why?
|
Aneuploidy | 1 | 2022 | 578 | 0.040 |
Why?
|
Protozoan Proteins | 1 | 2024 | 843 | 0.040 |
Why?
|
Mice, Inbred C57BL | 1 | 2016 | 22332 | 0.040 |
Why?
|
Thrombelastography | 1 | 2020 | 193 | 0.040 |
Why?
|
Cyclic GMP | 1 | 2019 | 394 | 0.040 |
Why?
|
Timolol | 1 | 2017 | 51 | 0.040 |
Why?
|
Kidney | 3 | 2018 | 7066 | 0.040 |
Why?
|
Vitamin A | 1 | 2020 | 610 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2019 | 14652 | 0.040 |
Why?
|
Pyridines | 1 | 2009 | 2888 | 0.040 |
Why?
|
Interleukin-10 | 1 | 2023 | 1183 | 0.040 |
Why?
|
2-Naphthylamine | 1 | 2017 | 20 | 0.040 |
Why?
|
Viremia | 1 | 2020 | 727 | 0.030 |
Why?
|
Hormones | 1 | 2021 | 863 | 0.030 |
Why?
|
Liver Diseases, Alcoholic | 1 | 2019 | 157 | 0.030 |
Why?
|
Catheters | 1 | 2020 | 426 | 0.030 |
Why?
|
Liver Failure, Acute | 1 | 2019 | 183 | 0.030 |
Why?
|
Seasons | 1 | 2023 | 1524 | 0.030 |
Why?
|
Bile Canaliculi | 1 | 2016 | 12 | 0.030 |
Why?
|
Macrocyclic Compounds | 1 | 2017 | 68 | 0.030 |
Why?
|
Polytetrafluoroethylene | 1 | 2018 | 238 | 0.030 |
Why?
|
Germany | 1 | 2019 | 882 | 0.030 |
Why?
|
Hepatic Encephalopathy | 1 | 2018 | 143 | 0.030 |
Why?
|
Elasticity | 1 | 2018 | 652 | 0.030 |
Why?
|
Adolescent | 1 | 2024 | 88835 | 0.030 |
Why?
|
Mice | 3 | 2018 | 81819 | 0.030 |
Why?
|
Coated Materials, Biocompatible | 1 | 2018 | 314 | 0.030 |
Why?
|
Drug Administration Routes | 1 | 2015 | 152 | 0.030 |
Why?
|
Stress, Physiological | 1 | 2023 | 1402 | 0.030 |
Why?
|
Chemoprevention | 1 | 2018 | 327 | 0.030 |
Why?
|
Ethanol | 1 | 2021 | 1323 | 0.030 |
Why?
|
Uracil | 1 | 2017 | 210 | 0.030 |
Why?
|
Time Factors | 4 | 2019 | 40065 | 0.030 |
Why?
|
Recombinant Proteins | 2 | 2015 | 6493 | 0.030 |
Why?
|
Cyclopropanes | 1 | 2017 | 437 | 0.030 |
Why?
|
Models, Animal | 1 | 2021 | 2120 | 0.030 |
Why?
|
Lactams, Macrocyclic | 1 | 2017 | 318 | 0.030 |
Why?
|
Recurrence | 2 | 2018 | 8501 | 0.030 |
Why?
|
Area Under Curve | 1 | 2019 | 1638 | 0.030 |
Why?
|
Ritonavir | 1 | 2017 | 330 | 0.030 |
Why?
|
Aftercare | 1 | 2021 | 911 | 0.030 |
Why?
|
Immunization | 1 | 2019 | 1219 | 0.030 |
Why?
|
Diuretics | 1 | 2018 | 613 | 0.030 |
Why?
|
Complement C5 | 1 | 2014 | 99 | 0.030 |
Why?
|
Quality of Life | 1 | 2016 | 13462 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2019 | 39193 | 0.030 |
Why?
|
Ligands | 1 | 2021 | 3273 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2022 | 1995 | 0.030 |
Why?
|
Complement C4 | 1 | 2014 | 208 | 0.030 |
Why?
|
Kidney Function Tests | 1 | 2016 | 683 | 0.030 |
Why?
|
Anilides | 1 | 2017 | 415 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2023 | 2132 | 0.030 |
Why?
|
Risk | 2 | 2015 | 9591 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 1 | 2009 | 5696 | 0.030 |
Why?
|
Drug Resistance, Viral | 1 | 2018 | 866 | 0.030 |
Why?
|
Intestinal Mucosa | 1 | 2024 | 3046 | 0.030 |
Why?
|
Common Bile Duct | 1 | 2013 | 106 | 0.030 |
Why?
|
Communicable Disease Control | 1 | 2019 | 856 | 0.020 |
Why?
|
Pressure | 1 | 2015 | 1168 | 0.020 |
Why?
|
Cytokines | 2 | 2022 | 7421 | 0.020 |
Why?
|
Alanine Transaminase | 1 | 2014 | 607 | 0.020 |
Why?
|
Collateral Circulation | 1 | 2013 | 292 | 0.020 |
Why?
|
Hemorrhage | 1 | 2023 | 3461 | 0.020 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2023 | 4348 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2018 | 1472 | 0.020 |
Why?
|
Longitudinal Studies | 2 | 2018 | 14751 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2022 | 5881 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4850 | 0.020 |
Why?
|
RNA | 1 | 2020 | 2717 | 0.020 |
Why?
|
Vaccines | 1 | 2019 | 841 | 0.020 |
Why?
|
Body Composition | 1 | 2020 | 2439 | 0.020 |
Why?
|
Anti-HIV Agents | 2 | 2017 | 4559 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2017 | 2721 | 0.020 |
Why?
|
Primary Prevention | 1 | 2018 | 1187 | 0.020 |
Why?
|
Glutathione | 1 | 2013 | 588 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2024 | 12437 | 0.020 |
Why?
|
Demography | 1 | 2014 | 1641 | 0.020 |
Why?
|
Anti-Retroviral Agents | 1 | 2019 | 1787 | 0.020 |
Why?
|
Mortality | 1 | 2020 | 2904 | 0.020 |
Why?
|
Nanoparticles | 1 | 2020 | 1964 | 0.020 |
Why?
|
Blood Flow Velocity | 1 | 2013 | 1381 | 0.020 |
Why?
|
Glomerular Filtration Rate | 1 | 2017 | 2233 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2017 | 6069 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2014 | 1789 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2014 | 3432 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3655 | 0.020 |
Why?
|
Niacinamide | 1 | 2009 | 419 | 0.020 |
Why?
|
Sulfonamides | 1 | 2017 | 1984 | 0.020 |
Why?
|
Extracellular Matrix | 1 | 2014 | 1727 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2013 | 2218 | 0.020 |
Why?
|
Vaccination | 1 | 2019 | 3426 | 0.020 |
Why?
|
Communication | 1 | 2020 | 3916 | 0.020 |
Why?
|
Treatment Failure | 1 | 2012 | 2652 | 0.020 |
Why?
|
Nitric Oxide Synthase Type III | 1 | 2009 | 707 | 0.020 |
Why?
|
Phenylurea Compounds | 1 | 2009 | 536 | 0.020 |
Why?
|
RNA, Viral | 1 | 2014 | 2864 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2018 | 8529 | 0.020 |
Why?
|
Sex Factors | 1 | 2019 | 10603 | 0.020 |
Why?
|
Administration, Oral | 1 | 2013 | 4015 | 0.010 |
Why?
|
Alleles | 1 | 2015 | 6897 | 0.010 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 3251 | 0.010 |
Why?
|
Up-Regulation | 1 | 2013 | 4137 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2014 | 6832 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2021 | 11888 | 0.010 |
Why?
|
Immunotherapy | 1 | 2019 | 4752 | 0.010 |
Why?
|
Research Design | 1 | 2018 | 6209 | 0.010 |
Why?
|
Down-Regulation | 1 | 2009 | 2927 | 0.010 |
Why?
|
Transcription Factors | 1 | 2021 | 12131 | 0.010 |
Why?
|
Heart Rate | 1 | 2013 | 4204 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2019 | 5370 | 0.010 |
Why?
|
Obesity | 1 | 2023 | 13076 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2023 | 15747 | 0.010 |
Why?
|
Hospitalization | 1 | 2020 | 10808 | 0.010 |
Why?
|
Incidence | 1 | 2019 | 21480 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2017 | 10383 | 0.010 |
Why?
|
Length of Stay | 1 | 2014 | 6485 | 0.010 |
Why?
|
Mutation | 1 | 2024 | 30198 | 0.010 |
Why?
|
Angiogenesis Inhibitors | 1 | 2009 | 2056 | 0.010 |
Why?
|
Age Factors | 1 | 2015 | 18380 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2018 | 18071 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2009 | 12768 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2009 | 10429 | 0.010 |
Why?
|